TriSalus Life Sciences推出优先证券交易所

2025-06-24 05:36

TriSalus Life Sciences (NASDAQ:TLSI) has initiated an exchange offer and consent solicitation to convert all Series A Convertible Preferred Stock into common stock.
Each preferred share will convert into common stock based on its total accrued value (including dividends through August 10, 2027), divided by $4/share.
The company is offering up to 11,860,206 shares of common stock in the exchange.
The move aims to reduce dilution risk, simplify the capital structure, and enhance equity transparency.
A consent solicitation proposes allowing automatic conversion of remaining preferred shares at a slightly lower exchange ratio (11.3% less) if approved.
The exchange offer expires at 12:01 a.m. ET on July 23, 2025.
Source: Press release

More on TriSalus Life Sciences